3 Companies at the Forefront of the GLP-1 Pill Wars

Industry Overview - The GLP-1 agonist market is projected to reach nearly $63 billion by early 2026, with forecasts indicating it could triple over the next decade [2] - The biopharma industry is rapidly developing new GLP-1 receptor agonist medications, with numerous firms involved in this growth [3] Company Focus: Eli Lilly - Eli Lilly and Company is a major player in the pharmaceutical industry, with a market capitalization nearing $1 trillion and shares increasing by almost 20% in the past year [4] - The company plans to invest $3 billion in China over the next decade to enhance its supply chain and local manufacturing capacity for GLP-1 medications, aiming to tap into the growing weight-loss market [5] - Eli Lilly has filed for approval of a new GLP-1 treatment, orforglipron, for obesity in the U.S. and over three dozen other countries, with a domestic launch expected by mid-2026 [6] Competitive Landscape - Eli Lilly's size and market position enable it to develop multiple GLP-1 medicines and expand globally [7] - Other companies to watch in the GLP-1 space include Viking Therapeutics and Structure Therapeutics, which are smaller but have promising GLP-1 candidates in clinical trials [7]